Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
Source: SeekingAlpha
2025-07-22 14:08:42 ET
Introduction
Replimune Group, Inc.'s ( REPL ) stock is reeling following the announcement that the company received a Complete Response Letter, CRL, from the FDA for its oncolytic immunotherapy, RP1. The company had submitted a Biologics License Application, or BLA, to utilize RP1 in combination with nivolumab (Opdivo) for the treatment of advanced melanoma....
Read the full article on Seeking Alpha
For further details see:
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-10.42% G/L:
$4.6493 Last:
4,448,331 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
